MA40232A - Procédé de purification de la protéine de fusion tnfr:fc - Google Patents

Procédé de purification de la protéine de fusion tnfr:fc

Info

Publication number
MA40232A
MA40232A MA040232A MA40232A MA40232A MA 40232 A MA40232 A MA 40232A MA 040232 A MA040232 A MA 040232A MA 40232 A MA40232 A MA 40232A MA 40232 A MA40232 A MA 40232A
Authority
MA
Morocco
Prior art keywords
tnfr
fusion protein
purification
present
hcp
Prior art date
Application number
MA040232A
Other languages
English (en)
French (fr)
Inventor
Abir Banerjee
Chandranath Ganapathy
Ashok Mishra
Sorab Rustom Mody
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MA40232A publication Critical patent/MA40232A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/30—Partition chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA040232A 2014-06-13 2015-06-13 Procédé de purification de la protéine de fusion tnfr:fc MA40232A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1919MU2014 2014-06-13

Publications (1)

Publication Number Publication Date
MA40232A true MA40232A (fr) 2017-04-19

Family

ID=53524922

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040232A MA40232A (fr) 2014-06-13 2015-06-13 Procédé de purification de la protéine de fusion tnfr:fc

Country Status (12)

Country Link
US (1) US10556942B2 (enExample)
EP (1) EP3155009A1 (enExample)
JP (1) JP6747985B2 (enExample)
CN (1) CN106536565A (enExample)
AU (1) AU2015273049B2 (enExample)
BR (1) BR112016029157A8 (enExample)
CA (1) CA2951766A1 (enExample)
MA (1) MA40232A (enExample)
MX (1) MX2016016318A (enExample)
PH (1) PH12016502482A1 (enExample)
RU (1) RU2698654C2 (enExample)
WO (1) WO2015189832A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US20180079796A1 (en) * 2015-03-13 2018-03-22 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
EP3455241B1 (en) 2016-05-11 2022-02-23 Cytiva BioProcess R&D AB Method of cleaning and/or sanitizing a separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
JP7122974B2 (ja) 2016-05-11 2022-08-22 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 変異免疫グロブリン結合ポリペプチド
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
MY199833A (en) * 2017-08-17 2023-11-24 Just Evotec Biologics Inc Method of purifying glycosylated protein from host cell galectins and other contaminants
EP3676281A1 (en) * 2017-08-30 2020-07-08 Ares Trading S.A. Method for purifying proteins
US11952399B2 (en) * 2018-12-18 2024-04-09 Amgen Inc. Methods for purifying proteins
MX2021008983A (es) * 2019-01-30 2021-09-08 Amgen Inc Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
WO2021181417A1 (en) * 2020-03-11 2021-09-16 Dr. Reddy's Laboratories Limited METHOD OF PURIFYING AN Fc-FUSION PROTEIN
CN113563469A (zh) * 2020-04-28 2021-10-29 江苏中新医药有限公司 高回收率纯化阿达木单抗的方法
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
EP4408857A4 (en) * 2021-09-28 2025-11-05 Kashiv Biosciences Llc IMPROVED PROCESS FOR PURIFICATION OF FUSION PROTEIN
CA3233419A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of protein
AU2022354256A1 (en) * 2021-09-28 2024-04-11 Kashiv Biosciences, Llc An improved process for purification of fusion protein
EP4421089A4 (en) * 2021-10-19 2026-01-07 Alteogen Inc METHOD FOR PURIFYING A FUSION PROTEIN HAVING AN IGG FC DOMAIN
US20250026784A1 (en) * 2021-11-29 2025-01-23 Tosoh Corporation Separation method of antibody
CN119060168A (zh) * 2024-09-26 2024-12-03 广东丸美生物技术股份有限公司 一种具有低电导率的重组胶原蛋白溶液及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021284C1 (ru) * 1991-05-30 1994-10-15 Всесоюзный научно-исследовательский институт технологии кровезаменителей и гормональных препаратов Способ очистки клинических фракций декстрана
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
CA2476934C (en) 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
WO2004076485A1 (en) 2003-02-28 2004-09-10 Lonza Biologics Plc. Antibody purification by protein a and ion exchange chromatography
US8263750B2 (en) * 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
JP2010501623A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ含有タンパク質の精製法
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
EP2203465A1 (en) * 2007-10-22 2010-07-07 Merck Serono S.A. Method for purifying an fc-containing protein
JP2011514895A (ja) * 2008-02-29 2011-05-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 精製免疫グロブリン融合タンパク質およびその精製方法
CN105646643A (zh) * 2008-10-29 2016-06-08 阿布林克斯公司 单域抗原结合性分子的纯化方法
EP2526114B1 (de) * 2010-01-22 2014-06-18 Boehringer Ingelheim International GmbH Chromatographisches verfahren zur aufreinigung von fc enthaltenden proteinen
EP2723759A4 (en) * 2011-06-24 2015-01-28 Reddys Lab Ltd Dr PURIFICATION OF CHIMERIC PROTEIN
JP6280499B2 (ja) * 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆｃ融合タンパク質の精製方法
ES2651483T3 (es) * 2011-08-17 2018-01-26 Ares Trading S.A. Método para preparar la forma activa de la proteína de fusión TNRF-Fc
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
KR102250937B1 (ko) * 2012-09-11 2021-05-12 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
CN102911250B (zh) 2012-09-29 2014-04-16 浙江海正药业股份有限公司 酸性重组蛋白药物的纯化方法
WO2014078627A1 (en) * 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Liquid formulations for tnfr:fc fusion proteins
PL3395423T3 (pl) * 2013-03-14 2024-03-18 Amgen Inc. Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography

Also Published As

Publication number Publication date
BR112016029157A8 (pt) 2021-07-06
US20170152298A1 (en) 2017-06-01
JP2017521389A (ja) 2017-08-03
RU2017100005A3 (enExample) 2019-02-28
MX2016016318A (es) 2017-06-12
RU2017100005A (ru) 2018-07-13
EP3155009A1 (en) 2017-04-19
JP6747985B2 (ja) 2020-08-26
WO2015189832A1 (en) 2015-12-17
PH12016502482A1 (en) 2017-04-10
AU2015273049A1 (en) 2017-01-12
RU2698654C2 (ru) 2019-08-28
BR112016029157A2 (pt) 2017-08-22
CN106536565A (zh) 2017-03-22
CA2951766A1 (en) 2015-12-17
AU2015273049B2 (en) 2019-11-14
US10556942B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
PH12016502482A1 (en) Process for the purification of tnfr:fc fusion protein
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
EP4299595A3 (en) Compositions and methods related to engineered fc constructs
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2022009875A (es) Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
MX384346B (es) Bloqueo de cd73.
MX358137B (es) Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.
MX391632B (es) Proteasa de cisteína.
ZA201705113B (en) Cysteine protease
MX375524B (es) Anticuerpos anti-axl.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
SG10201907582WA (en) Bicyclic heterocycles as fgfr4 inhibitors
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
IN2014DN08721A (enExample)
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.